Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations by Marina C. Garassino, MD, Sabine Oskar, PhD, MPH, Ashwini Arunachalam, MPH, BDS, Ke Zu, PhD, ScD, MPH, Yu-Han Kao, PhD, Cai Chen, PhD, Weilin Meng, MEng, M. Catherine Pietanza, MD, Bin Zhao, MD, Himani Aggarwal, MPhil, PhD

Get full text

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC by Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD

Get full text

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC by Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD

Get full text